ÂÜÀòÂÒÂ×

Sally Collins is an accomplished pharmaceutical executive with extensive experience in sales and marketing leadership across several prominent companies. Currently serving as Vice President and US Business Lead for TTR at Alnylam Pharmaceuticals since March 2022, Sally previously held multiple senior roles at Alexion Pharmaceuticals, including Vice President of the U.S. Metabolics Business Unit and Executive Director, Head of Sales. Earlier career experiences include leadership positions in oncology at Boehringer Ingelheim and roles at Cephalon and Shire Pharmaceuticals. Sally holds a Bachelor's Degree with Honors in Psychology from the University of Sunderland.